培训、推动数智医疗政策支持与监管的强化优化和适老化等方面发力，让数智医疗服务真正成为提升老 年群体健康福祉的"助力器"，而非"拦路虎"。 （作者为南京医科大学数智技术与健康治理实验室教授；本文系国家自然科学基金"多元共同决策视角 下慢性病共病管理模式构建、评价与优化：基于社区干预试验"〈项目编号：72174093〉、国家自然科 学基金"基于行动者网络理论的慢病医防融合激励机制设计与行动干预策略研究"〈项目编号： 72474109〉的研究成果） 数智医疗技术通过可穿戴设备、物联网和人工智能等，助力疾病预防和慢性病管理。基于大数据分析结 果，AI可预测老年人患病风险（如跌倒、心血管疾病等），并提供个性化咨询建议。美国AliveCor公司 的AI心电图技术，通过手机APP采集心电数据，能够迅速识别异常心律（如房颤、早搏等），预防和降 低老年人突发心脏病风险。智能手表、手环、血压血糖监测仪等设备可实时记录老年人的心率、血氧、 睡眠质量等数据，并可同步至云端或其子女及医护人员终端。华为Watch D支持血压测量和异常预警， 适用于高血压老年群体；欧姆龙智能血糖仪通过蓝牙连接APP，自动生成血糖曲线，辅助糖尿病管理。 数 ...

Core Viewpoint - Lenovo Star has successfully nurtured and invested in the biopharmaceutical sector, culminating in six notable IPOs, including the recent listing of Paig Bio, which reflects the company's long-term commitment and strategic focus in the healthcare investment landscape [1][7]. Investment Journey - Lenovo Star's relationship with Paig Bio began in 2010, marking the company's entry into the biopharmaceutical investment space, particularly in the Suzhou Biopharmaceutical Industry Park [2]. - The investment decision was influenced by Paig Bio's innovative GLP-1 receptor agonist, PB-119, which shows promising results in treating type 2 diabetes and obesity, alongside a significant market need in China [3]. Development and Support - Over the years, Lenovo Star provided continuous support to Paig Bio, including a follow-up investment of $1.2 million in 2014, which helped the company advance its product development [4]. - Paig Bio has developed six candidate products, with PB-119 expected to receive approval for commercialization in China by mid-2025 [4]. Financial Returns - The successful IPO of Paig Bio has yielded a 13-fold return on investment for Lenovo Star, highlighting the value of its long-term investment strategy in the biopharmaceutical sector [5][6]. Broader Investment Ecosystem - Lenovo Star has established a robust investment ecosystem in healthcare, having invested in over 100 quality medical projects, including notable companies like Kintor Pharmaceutical and Burning Rock Biotech [7]. - The firm has focused on two main segments: biopharmaceuticals and smart healthcare, leveraging advancements in AI and big data to enhance drug development and healthcare services [7][8]. Strategic Focus and Future Outlook - Lenovo Star's mission, established in collaboration with the Chinese Academy of Sciences, is to discover and cultivate tech entrepreneurship, with a strong emphasis on biopharmaceuticals due to the growing demand for innovative drugs in China [8][9]. - The company anticipates a turning point in the healthcare sector by 2026, driven by a combination of technological advancements and a growing demand for effective healthcare solutions [12].